TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.
创建时间：
2019-03-15
